PUBLISHER: KBV Research | PRODUCT CODE: 1276589
PUBLISHER: KBV Research | PRODUCT CODE: 1276589
The Europe Sterility Testing Market would witness market growth of 9.8% CAGR during the forecast period (2023-2029).
In the sterilization, validation, and release testing phases of pharmaceutical manufacture, sterility testing is crucial. It plays a crucial role in many industries' sterilization validation processes, making it an important manufacturing procedure. It is a very tough process that needs to be well planned and carried out, which can help to weed out false positive results. False positive results are typically caused by lab contamination or staff error. Planned testing should be done in a spotless environment with little to no potential for error.
Additionally, this would guarantee that the viable microbial air & surface counts meet U.S. Pharmacopeia (USP) standards. The rules for good manufacturing practices restrict the use of sterility testing methodologies as an official test and the determination of appropriateness. It is necessary to provide suitable and accurate sterility test data to understand the benefits of sterility testing in the validation process and planning. Additionally, sterility testing is a laborious and artistic process that qualified personnel must carry out. Additionally, a thorough examination of environmental data and other elements, like sample collecting and sample procurement methods, is required during the investigative phase of a failed sterility test.
In Russia, each person spent an average of $140 on prescription drugs in 2018. Around $20.1 billion in pharmaceuticals were sold in Russia that same year, accounting for 1.2% of the country's GDP and 22.1% of all health expenditures. Both prescription and over the counter (OTC) medications fall within the pharmaceutical industry in Russia. In general, sales of prescription drugs dominated the pharmaceutical industry, which persisted in 2018 prescription drugs. The use of drugs containing gelatin will increase due to the developing healthcare industry and increased funding. The pharma industry in this region is expected to grow due to this expansion, which will increase demand for sterility testing.
The Germany market dominated the Europe Sterility Testing Market by Country in 2022; thereby, achieving a market value of $133.1 million by 2029. The UK market is exhibiting a CAGR of 8.8% during (2023 - 2029). Additionally, The France market would experience a CAGR of 10.6% during (2023 - 2029).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Test Type, the market is segmented into Membrane Filtration, Direct Inoculation and Others. Based on Application, the market is segmented into Pharmaceuticals & Biologicals, Medical Devices and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., SGS S.A., Merck KGaA, BioMerieux S.A., WuXi AppTec Co., Ltd., Sartorius AG, Samsung Biologics Co., Ltd. (Samsung Group), Nelson Laboratories, LLC (Sotera Health Company) and Pacific Biolabs, Inc.
Market Segments covered in the Report:
By Product
By Test Type
By Application
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
List of Figures